Biotechnology is a popping business in the first half of 2013 and, considering the solid ascending trend, it seems like the field will endure to surpass the Dow, S&P 500 and Nas daq in the last half of the year as well. In fact, the Nasdaq Biotec_hnology Index (NBI) has surpassed the three big indexes every year since 2008 and started really increasing speed in the last three months of 2011. Through the first six months of this year, NBI is ahead by 30% while the S&P 500 has shown gains of about half of that at 16%.
Starting biotechs with encouraging technologies can bring epic profits to savvy investors, clarifying why institutions and stores keep investing into it in all market conditions. For example, shares of Clovis Oncology (C.L.V.S), a biotech with a small pipeline that the most advanced candidates are only in Level I/II trials, have exploded since the entity went public in Nov. 2-0-1-1. Shares were selling around $12 each at that time and are currently at $75. While that may be a bit out of the price range now for many investors looking for maximum gains, there are other options for undervalued biote-chs.
Plandai Biotec_hnology (P-L-P-L) looks to be seizing the attention of Wall Street, rising a astounding eight hundred percent in the first half of 2-0-1-3. Yet, the entity still only commands a per share price approximately fifty cents. Plan-dai is nearing commer-cialization of its extract technology that could revolutionize the multi-bil_lion dollar neutraceutical market.
Basically speaking, the chart is positioned for another breakout trailing a consolidation subsequent to new levels of 62 cents in May. Every experienced trader knows that a perfect storm is when fundamentals and technicals merge, making Plan dai Biotec_hnology (P-L-P-L) a organization to keep an eye on in the near future!
